Roche Digs In To Early Breast Cancer With New Perjeta Approvals
Roche's HER2 franchise got a boost with new early breast cancer approvals for Perjeta. Above, immunohistochemistry for HER2 shows positive cell membrane staining in infiltrating ductal carcinoma.
